PMID- 31742778
OWN - NLM
STAT- MEDLINE
DCOM- 20200703
LR  - 20211204
IS  - 1099-1573 (Electronic)
IS  - 0951-418X (Linking)
VI  - 34
IP  - 3
DP  - 2020 Mar
TI  - Ganoderic Acid A exerts the cytoprotection against hypoxia-triggered impairment 
      in PC12 cells via elevating microRNA-153.
PG  - 640-648
LID - 10.1002/ptr.6556 [doi]
AB  - Ganoderic Acid A (GAA) is often applied for healing cardiovascular and 
      cerebrovascular ailments, but the influences in cerebral ischemia injury are 
      still hazy. The research delved into the functions of GAA in hypoxia-triggered 
      impairment in PC12 cells. PC12 cells received hypoxia management for 12 hr, and 
      subsequently, cell viability, migration, apoptosis, and correlative protein 
      levels were assessed. After preprocessing with GAA, above cell behaviors were 
      monitored again. The vector of microRNA (miR)-153 inhibitor was utilized for PC12 
      cell transfection to further explore the functions of miR-153 in hypoxia-impaired 
      cells. Pathways of phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) 
      and mammalian target of rapamycin (mTOR) were investigated via executing western 
      blot for uncovering the latent mechanism. Results revealed that hypoxia 
      disposition triggered PC12 cells impairment via restraining cell viability and 
      migration and accelerating apoptosis. However, GAA visibly mollified 
      hypoxia-provoked impairment in PC12 cells. Interestingly, the enhancement of 
      miR-153 triggered by GAA was observed in hypoxia-impaired PC12 cells. After 
      miR-153 inhibitor transfection, the protective functions of GAA in 
      hypoxia-impaired PC12 cells were dramatically inversed. Furthermore, GAA caused 
      PI3K/AKT and mTOR activations via enhancement of miR-153 in hypoxia-impaired PC12 
      cells. The findings evinced that GAA exhibited the protective functions in PC12 
      cells against hypoxia-evoked impairment through activating PI3K/AKT and mTOR via 
      elevating miR-153.
CI  - (c) 2019 John Wiley & Sons, Ltd.
FAU - Li, Hong
AU  - Li H
AD  - Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, 
      Shandong, China.
FAU - Lou, Bo
AU  - Lou B
AD  - Department of Rehabilitation Medicine, The Third People's Hospital of Liaocheng, 
      Liaocheng, Shandong, China.
FAU - Zhang, Yingying
AU  - Zhang Y
AD  - Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao, 
      Shandong, China.
FAU - Zhang, Changyuan
AU  - Zhang C
AUID- ORCID: 0000-0001-8584-6168
AD  - Department of Pharmacy, Jining No.1 People's Hospital, Jining, Shandong, China.
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20191119
PL  - England
TA  - Phytother Res
JT  - Phytotherapy research : PTR
JID - 8904486
RN  - 0 (Heptanoic Acids)
RN  - 0 (MIRN153 microRNA, rat)
RN  - 0 (MicroRNAs)
RN  - 1J05Z83K3M (Lanosterol)
RN  - 548G37DF65 (ganoderic acid A)
RN  - EC 2.7.1.1 (mTOR protein, rat)
RN  - EC 2.7.11.1 (Oncogene Protein v-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
RIN - Phytother Res. 2020 Dec;34(12):3434. PMID: 33301239
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Cell Hypoxia
MH  - Cell Survival/drug effects
MH  - Cytoprotection/*drug effects
MH  - Heptanoic Acids/*pharmacology
MH  - Lanosterol/*analogs & derivatives/pharmacology
MH  - MicroRNAs/*genetics
MH  - Oncogene Protein v-akt/metabolism
MH  - PC12 Cells
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Rats
MH  - TOR Serine-Threonine Kinases/metabolism
OTO - NOTNLM
OT  - Ganoderic Acid A
OT  - PI3K/AKT/mTOR pathway
OT  - cell injury
OT  - hypoxia
OT  - microRNA-153
EDAT- 2019/11/20 06:00
MHDA- 2020/07/04 06:00
CRDT- 2019/11/20 06:00
PHST- 2019/08/29 00:00 [received]
PHST- 2019/10/23 00:00 [revised]
PHST- 2019/10/28 00:00 [accepted]
PHST- 2019/11/20 06:00 [pubmed]
PHST- 2020/07/04 06:00 [medline]
PHST- 2019/11/20 06:00 [entrez]
AID - 10.1002/ptr.6556 [doi]
PST - ppublish
SO  - Phytother Res. 2020 Mar;34(3):640-648. doi: 10.1002/ptr.6556. Epub 2019 Nov 19.